L-alpha-Aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-L-methioninamide

Basic Information

View in Editor

CAS Number

122063-01-8

Molecular Formula

C35H56N8O10S

Molecular Weight

780.95 g/mol

Chemical Classification

Basic Chemical Raw Materials Organic Chemicals Carboxylic Acids

Basic Chemical Raw Materials Organic Chemicals Amines

Fine Chemicals Dyes and Pigments Organic Dyes

Fine Chemicals Surfactants Anionic Surfactants

Basic Physical Properties

Boiling Point

1236.1°Cat760mmHg

Density

1.265

Flash Point

701.3°C

Refractive Index

1.563

SMILES

View in Editor

CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CCNC(=O)C(C(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CO)NC(=O)C(CC(=O)O)N

InChI

InChI=1S/C35H56N8O10S/c1-19(2)15-24(32(50)40-23(30(37)48)12-14-54-5)39-27(45)11-13-38-35(53)29(20(3)4)43-33(51)25(16-21-9-7-6-8-10-21)41-34(52)26(18-44)42-31(49)22(36)17-28(46)47/h6-10,19-20,22-26,29,44H,11-18,36H2,1-5H3,(H2,37,48)(H,38,53)(H,39,45)(H,40,50)(H,41,52)(H,42,49)(H,43,51)(H,46,47)/t22-,23-,24-,25-,26-,29-/m0/s1

InChIKey

CKNPSJOMUQBPLA-WTWMNNMUSA-N

LogP

-2.105799999999997

Topological Polar Surface Area

301.23999999999995 Å²

Hydrogen Bond Donor/Acceptor

12 / 18

Complexity

1280

Synonyms & References

English

HY-P1031
(b-Ala8)-Neurokinin A (4-10)
(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[3-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-oxopropyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
CS-7598
CHEMBL1875296
AKOS024456720
L-Methioninamide,l-a-aspartyl-L-seryl-L-phenylalanyl-L-valyl-b-alanyl-L-leucyl-
(3S)-3-AMINO-3-{[(1S)-1-{[(1S)-1-{[(1S)-1-[(2-{[(1S)-1-{[(1S)-1-CARBAMOYL-3-(METHYLSULFANYL)PROPYL]CARBAMOYL}-3-METHYLBUTYL]CARBAMOYL}ETHYL)CARBAMOYL]-2-METHYLPROPYL]CARBAMOYL}-2-PHENYLETHYL]CARBAMOYL}-2-HYDROXYETHYL]CARBAMOYL}PROPANOIC ACID
MEN 10210
122063-01-8
Asp-Ser-Phe-Val-beta-Ala-Leu-Met-NH2
XEA06301
[bAla8]-Neurokinin A(4-10)
MFCD00143686
AS-80269
L-Methioninamide, L-alpha-aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-
(5S,8S,15S,18S,21S,24S)-24-amino-18-benzyl-5-carbamoyl-21-(hydroxymethyl)-8-isobutyl-15-isopropyl-7,10,14,17,20,23-hexaoxo-2-thia-6,9,13,16,19,22-hexaazahexacosan-26-oic acid
NCGC00167336-01
L-Methioninamide, L-a-aspartyl-L-seryl-L-phenylalanyl-L-valyl-b-alanyl-L-leucyl-
[BALA8]-NEUROKININ A(4-10)
ASP-SER-PHE-VAL-B-ALA-LEU-MET-NH2
Asp-ser-phe-val-beta-ala-leu-met-nh2
DSFVXLM
M.W. 780.93 C35H56N8O10S
NK2 TACHYKININ RECEPT
DSFV-BETA-ALM
DSFV-(BETA-A)-LM-NH2
M.W. 780.93 C35H56N8O10S
(BETA-ALA8)-NEUROKININ A (4-10)
neurokinin A (4-10), beta-Ala(8)-
H-ASP-SER-PHE-VAL-BETA-ALA-LEU-MET-NH2

MDL Number

MFCD00143686

FAQ

What regulatory guidelines apply to L-alpha-Aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-L-methioninamide (CAS: 122063-01-8)?

L-alpha-Aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-L-methioninamide (CAS: 122063-01-8) is subject to various regulatory guidelines. For instance, under GHS (Globally Harmonized System of Classification and Labeling of Chemicals), this compound may require specific hazard communication labels and safety data sheets. In Europe, it is regulated under REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) where detailed information on its properties and uses must be provided. Additionally, the FDA and EPA may have specific requirements for its manufacturing, storage, and disposal, particularly if it is used in pharmaceuticals or other regulated products.

Are there alternatives to L-alpha-Aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-L-methioninamide in synthesis?

There are several alternatives to L-alpha-Aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-L-methioninamide (CAS: 122063-01-8) in synthesis. For example, different amino acid sequences or similar peptides can be used depending on the desired biological activity. Other alternatives might include isomers or analogs that share similar functional groups but have different side chains or other modifications. These alternatives can offer similar or enhanced functional properties while potentially reducing toxicity or increasing stability.

What is the market or research trend for L-alpha-Aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-L-methioninamide (CAS: 122063-01-8)?

The market and research trends for L-alpha-Aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-L-methioninamide (CAS: 122063-01-8) are predominantly focused on its potential applications in biotechnology and pharmaceuticals. This compound is a complex peptide that shows promise in various research areas, including drug discovery and targeted therapy. Recent studies highlight its use in developing novel treatments for diseases such as cancer and neurodegenerative disorders. Additionally, there is growing interest in its potential as a therapeutic agent, which could lead to increased demand and investment in related research.

How should waste containing L-alpha-Aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-L-methioninamide (CAS: 122063-01-8) be handled?

Waste containing L-alpha-Aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-L-methioninamide (CAS: 122063-01-8) should be handled with caution to ensure environmental and worker safety. Proper collection and segregation of waste are crucial. Waste liquids should be collected in appropriate containers and stored according to the facility's hazardous waste management plan. For solid waste, ensure it is disposed of through a licensed professional waste disposal service. Environmental protection precautions include minimizing spills and ensuring all waste is treated or disposed of in accordance with local and national regulations. Proper training and use of personal protective equipment (PPE) are also essential during handling and disposal processes.